Outcomes:
For non-metastatic OGS, at a median follow-up of 59.7 (95% confidence interval (CI): 54.4-63.3) months, 5-year event free survival (5-EFS) was 54.8 (CI: 50.5-59.4)%, and 5-year overall survival (5-OS) was 72.7 (CI: 68.7-77.0)%. For metastatic OGS, 5-EFS was 18.7 (CI: 12.7-27.5)%. For non-metastatic and metastatic ES, 5-EFS were 68.8 (CI: 59.5-79.5)% and 21.9% (CI 11.4-42.0)%.